Athena Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Athena Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$779K	Buy	+1,568	New	+$695K	0.58%	47

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

Athena Wealth Management's VRTX Position: Q2 2026 in Review

Athena Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1,568 shares worth $779K. The stake represents 0.58% of the portfolio and ranks #47 among its holdings.

368 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Athena Wealth Management held 1,568 shares of Vertex Pharmaceuticals worth $779K as of Q2 2026.
Vertex Pharmaceuticals was a new Athena Wealth Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.58% of Athena Wealth Management's portfolio in Q2 2026, its #47 holding.
368 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Athena Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.